Clinical studies have confirmed the safety of low‐dose IL‐2 in therapying various autoimmune and inflammatory chronic diseases (including RA, ankylosing spondylitis, SLE, and psoriasis).4 The gene discussed is IL2; the disease is systemic lupus erythematosus.